https://www.biopharmadive.com/news/asco17-astrazenecas-lynparza-stays-step-ahead-of-parp-rivals/444152/
Data showing a 42% risk reduction in disease worsening compared to chemo in breast cancer patients should help build Lynparza's profile outside of ovarian...
step aheadastrazenecalynparzastaysparp
https://www.pharmaceutical-technology.com/news/astrazeneca-results-solo3-lynparza-cancer/
AstraZeneca and its partner Merck have published positive results from SOLO-3 phase III trial of Lynparza indicated for advanced ovarian cancer.
positive resultsastrazenecaannouncessolotrial